Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Featured

Blog

The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult

Blog

USPTO Limits Use of General Knowledge in IPR Proceedings

Article

Broad Prosecution History Estoppel Decision Shows Risk of Relying on Doctrine of Equivalents

Blog

A New FRAND Framework: India Embraces Interim Security to Deter SEP Hold-Out

Blog

Developing Issues in Patent Damages: Future Royalties

Authored by: Chris Marchese, Tim J. Rawson

Blog | January 15, 2026

5 in ’25: Appellate

Blog | January 09, 2026

5 in ’25: Standard Essential Patents

Blog | January 07, 2026

5 in ’25: Artificial Intelligence

Blog | January 06, 2026

PTAB Reverses § 101 Rejection Under Desjardins Framework

Blog | December 31, 2025

USPTO Launches SEP Working Group

Blog | December 30, 2025

Court Declines To Lift 30-Month Stay To Prevent Alleged Unfair Competitive Advantage Between Generics

Blog | December 30, 2025

UK High Court Clarifies Scope of SPC Waiver Notification Requirements

Blog | December 29, 2025

Lessons From Recent Pharma & Med Device Federal Circuit Decisions

Blog | December 22, 2025

5 in ‘25: International Trade Commission

Blog | December 17, 2025

Texas Round-Up: November 2025

Article | December 15, 2025

Federal Circuit Declines To Disturb “Settled Expectations” Factor in Denying Mandamus Petitions

Blog | December 10, 2025

USPTO Adds Desjardins to MPEP Subject Matter Eligibility Guidance